Note 4 - Personnel Expenses, Including Share-based Remuneration (Tables)
|
12 Months Ended |
Dec. 31, 2023 |
Statement Line Items [Line Items] |
|
Disclosure of personnel expenses including share-based remuneration [text block] |
| | Year ended December 31, | |
| | 2021 | | | 2022 | | | 2023 | |
Salaries, including bonuses | | $ | 43,440 | | | $ | 43,235 | | | $ | 41,890 | |
Social security contribution, excluding amounts related to share-based remuneration | | | 5,371 | | | | 5,222 | | | | 5,825 | |
External temporary hires | | | 8,617 | | | | 10,318 | | | | 11,796 | |
Defined contribution pension expense | | | 4,477 | | | | 4,752 | | | | 3,814 | |
Other personnel-related expenses | | | 2,080 | | | | 1,758 | | | | 2,476 | |
Total personnel expenses, excluding share-based remuneration | | | 63,984 | | | | 65,285 | | | | 65,801 | |
Share-based remuneration, including related social security contribution | | | 10,466 | | | | 9,304 | | | | 16,950 | |
Total personnel expenses, including share-based remuneration | | $ | 74,450 | | | $ | 74,588 | | | $ | 82,750 | |
|
Disclosure of research and development expense [text block] |
| | Year ended December 31, | |
| | 2021 | | | 2022 | | | 2023 | |
Total research and development expenditure | | | 44,055 | | | | 50,537 | | | | 46,098 | |
Less: Capitalized development expenditure excluded from personnel expenses (Note 10) | | | 4,862 | | | | 6,825 | | | | 4,587 | |
Net research and development expenditure recognized as part of personnel expenses | | | 39,193 | | | | 43,713 | | | | 41,511 | |
|
Disclosure of number and weighted average exercise prices of share options and other equity instruments [text block] |
| | Opera: RSUs | | | Opera: Options | | | Kunlun: RSUs (1) | |
| | Number of RSUs | | | Weighted average grant date fair value | | | Number of options | | | Weighted average grant date fair value | | | Number of RSUs | | | Weighted average grant date fair value | |
Outstanding as of January 1, 2022 | | | 2,666,525 | | | $ | 9.71 | | | | 100,000 | | | $ | 3.40 | | | | - | | | $ | - | |
Granted during the year | | | - | | | | - | | | | - | | | | - | | | | 3,275,000 | | | | 1.22 | |
Forfeited during the year | | | (82,500 | ) | | | 9.97 | | | | - | | | | - | | | | (350,000 | ) | | | 1.22 | |
Exercised during the year | | | (798,750 | ) | | | 9.25 | | | | - | | | | - | | | | - | | | | - | |
Expired during the year | | | - | | | | - | | | | - | | | | - | | | | - | | | | - | |
Outstanding as of December 31, 2022 | | | 1,785,275 | | | | 9.90 | | | | 100,000 | | | | 3.40 | | | | 2,925,000 | | | | 1.22 | |
Regular grants during the year | | | 934,359 | | | | 8.39 | | | | - | | | | - | | | | 6,200,000 | | | | 2.01 | |
Dividend adjustment grants during the year | | | 257,551 | | | | - | | | | - | | | | - | | | | - | | | | - | |
Forfeited during the year | | | (50,203 | ) | | | 8.66 | | | | - | | | | - | | | | (2,000,000 | ) | | | 1.68 | |
Exercised during the year | | | (1,008,509 | ) | | | 8.37 | | | | (60,000 | ) | | | 1.92 | | | | (832,500 | ) | | | 1.10 | |
Expired during the year | | | - | | | | - | | | | - | | | | - | | | | - | | | | - | |
Outstanding as of December 31, 2023 | | | 1,918,473 | | | $ | 8.67 | | | | 40,000 | | | $ | 5.62 | | | | 6,292,500 | | | $ | 1.86 | |
|
Disclosure of indirect measurement of fair value of goods or services received, other equity instrument granted during period [text block] |
| | Opera 2023 RSU grants (2) | | | Kunlun 2022 RSU grants | | | Kunlun 2023 RSU grants | |
Equity unit price valuation | | $ | 8.46 | | | $ | 2.88 | | | $ | 3.48 | |
Model Used | | Monte Carlo | | | Black-Scholes | | | Black-Scholes | |
Expected Volatility (%) (1) | | | 50.5 | % | | | 25.5 | % | | | 24.6 | % |
Risk free interest rate (%) (1) | | | 4.9 | % | | | 2.2 | % | | | 2.1 | % |
Duration of initial simulation period (years to longstop date) | | | 2.49 | | | | N/A | | | | N/A | |
Duration of second simulation period with postponed exercise (years) | | | 3.00 | | | | N/A | | | | N/A | |
Exercise price | | $ | - | | | $ | 1.77 | | | $ | 1.54 | |
Fair value at the measurement date | | $ | 8.39 | | | $ | 1.22 | | | $ | 2.01 | |
|
Disclosure of information about key management personnel [text block] |
| | Year ended December 31, | |
| | 2021 | | | 2022 | | | 2023 | |
Short-term employee benefits | | $ | 2,046 | | | $ | 2,371 | | | $ | 2,495 | |
Post-employment and medical benefits | | | 60 | | | | 56 | | | | 72 | |
Share-based payment transactions | | | 1,209 | | | | 1,488 | | | | 1,693 | |
Total compensation for key management personnel | | $ | 3,315 | | | $ | 3,914 | | | $ | 4,260 | |
|